Treatment-Induced Thrombocytopenia | Risk Factors for Severe Menorrhagia

 

Patient selection: high-dose chemotherapy with stem cell or bone marrow transplant

 

Moderate vaginal bleeding was defined as a blood loss comparable to the patient's regular menstruation and requiring a medical intervention.

 

Severe vaginal bleeding was defined as a blood loss exceeding the patient's regular menstruation and requiring medical and/or surgical intervention.

 

Factors associated with severe menorrhagia:

(1) menses in premenopausal women

(2) uterine pathology associated with uterine bleeding

(3) severity of thrombocytopenia (severe if platelet count < 25,000 per µL)

(4) prolonged thrombocytopenia

(5) antiplatelet drugs

(6) other coagulation abnormalities

 

The use of the gonadotropin-releasing hormone agonist (GnRh-a) was associated with amenorrhea in premenopausal women, which reduced menorrhagia. Control of bleeding was superior to that seen with depo-medroxyprogesterone acetate (DMPA).